These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 38180130)
1. Enabling continuous immune cell recirculation on a microfluidic array to study immunotherapeutic interactions in a recapitulated tumour microenvironment. Chi CW; Lao YH; Ahmed AHR; He S; Merghoub T; Leong KW; Wang S Lab Chip; 2024 Jan; 24(3):396-407. PubMed ID: 38180130 [TBL] [Abstract][Full Text] [Related]
2. High-throughput microfluidic 3D biomimetic model enabling quantitative description of the human breast tumor microenvironment. Berger Fridman I; Kostas J; Gregus M; Ray S; Sullivan MR; Ivanov AR; Cohen S; Konry T Acta Biomater; 2021 Sep; 132():473-488. PubMed ID: 34153511 [TBL] [Abstract][Full Text] [Related]
3. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment. Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040 [TBL] [Abstract][Full Text] [Related]
4. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811 [TBL] [Abstract][Full Text] [Related]
6. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy. Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478 [TBL] [Abstract][Full Text] [Related]
7. Control of Dendritic Cell Function Within the Tumour Microenvironment. Gupta YH; Khanom A; Acton SE Front Immunol; 2022; 13():733800. PubMed ID: 35355992 [TBL] [Abstract][Full Text] [Related]
8. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist. Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618 [TBL] [Abstract][Full Text] [Related]
9. Tumor microenvironment signaling and therapeutics in cancer progression. Goenka A; Khan F; Verma B; Sinha P; Dmello CC; Jogalekar MP; Gangadaran P; Ahn BC Cancer Commun (Lond); 2023 May; 43(5):525-561. PubMed ID: 37005490 [TBL] [Abstract][Full Text] [Related]
10. Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition. Lu L; Gao Y; Huang D; Liu H; Yin D; Li M; Zheng J; Wang S; Wu W; Zhao L; Bi D; Zhang Y; Song F; Xie R; Wang J; Qin H; Wei Q J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040421 [TBL] [Abstract][Full Text] [Related]
11. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399 [TBL] [Abstract][Full Text] [Related]
12. Targeting the immune microenvironment for ovarian cancer therapy. Blanc-Durand F; Clemence Wei Xian L; Tan DSP Front Immunol; 2023; 14():1328651. PubMed ID: 38164130 [TBL] [Abstract][Full Text] [Related]
13. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells. Yong SB; Chung JY; Song Y; Kim J; Ra S; Kim YH Biomaterials; 2019 Oct; 219():119401. PubMed ID: 31398571 [TBL] [Abstract][Full Text] [Related]
14. Tumor-on-a-chip platforms to study cancer-immune system crosstalk in the era of immunotherapy. Parlato S; Grisanti G; Sinibaldi G; Peruzzi G; Casciola CM; Gabriele L Lab Chip; 2021 Jan; 21(2):234-253. PubMed ID: 33315027 [TBL] [Abstract][Full Text] [Related]
15. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy. Das S; Valton J; Duchateau P; Poirot L Front Immunol; 2023; 14():1172681. PubMed ID: 37251405 [TBL] [Abstract][Full Text] [Related]
16. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma. Noh BJ; Kwak JY; Eom DW BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245 [TBL] [Abstract][Full Text] [Related]
17. Fabrication of a self-assembled and vascularized tumor array Lee G; Kim SJ; Park JK Lab Chip; 2023 Sep; 23(18):4079-4091. PubMed ID: 37614164 [TBL] [Abstract][Full Text] [Related]
18. Direct and indirect engagement of dendritic cell function by antibodies developed for cancer therapy. Corogeanu D; Diebold SS Clin Exp Immunol; 2022 Jul; 209(1):64-71. PubMed ID: 35352109 [TBL] [Abstract][Full Text] [Related]
19. CD8 Zheng X; Jiang K; Xiao W; Zeng D; Peng W; Bai J; Chen X; Li P; Zhang L; Zheng X; Miao Q; Wang H; Wu S; Xu Y; Xu H; Li C; Li L; Gao X; Zheng S; Li J; Wang D; Zhou Z; Xia X; Yang S; Li Y; Cui Z; Zhang Q; Chen L; Lin X; Lin G Front Immunol; 2022; 13():974265. PubMed ID: 36439099 [TBL] [Abstract][Full Text] [Related]
20. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Yang CY; Lin MW; Chang YL; Wu CT; Yang PC Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]